Page 217 - Eceptor News Today

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells New antivirals are being sought worldwide to fight back the ever-growing threat of the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has already claimed more than three million human lives. A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry ...

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Soo-Young Lee from Celltrion Inc., in Incheon and colleagues, found that al...

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease Researchers in the United States have provided important insights into the pathophysiology of diarrhea that occurs in some cases of coronavirus disease 2019 (COVID-19). The team says the “COVID-19 diarrhea” that may develop following infection with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the first example of viral diarrhea that is dependent on the inflammatory respons...

In a new study currently available on the bioRxiv* preprint server, a group of US-based researchers developed a panel of neutralizing monoclonal antibodies against SARS-CoV-2 that can block viral attachment to cells – and pinpointed a specific one that can potently neutralize all tested variants of concern.

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States. But a team of researchers at Fralin Biomedical Research Institute at VTC and City of Hope, a comprehensive care center, believes the comp...

Topical therapy can help safely reduce side effect of cancer treatment Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center. For the past decade, epidermal growth factor receptor (EGFR) inhibitors have helped prolong...

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The team analyzed the impact of potential mutations in the spike receptor-binding domain (RBD) on antibody efficacy. The study is currently available on the Backgroun...

Why do we lose our sense smell/taste with COVID? The angiotensin-converting enzyme 2 (ACE2) enzyme attached to the membranes of cells is the entry point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They are abundantly found all over the body and most prominently in the lungs and nose. This coincides with initial symptoms exhibiting loss of smell and respiratory problems. Another early symptom of SARS-CoV-2 infection is loss of taste, although the mechanism of why this happe...

A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.

Can control theory explain differences in virulence and transmission of SARS-CoV-2? The currently raging pandemic of coronavirus disease 2019 (COVID-19) is taking more lives today than over the first five months after its onset. The difficulty in gaining control of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stems partly from the fact that most infections are asymptomatic or very mild. Moreover, the frequent emergence of escape variants that overcome immune inhibition elici...